Trial Profile
Eicosapentaenoic acid role in preventing periprocedural (Type IVa) myocardial infarction in patients undergoing percutaneous coronary intervention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2015
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid (Primary) ; HMG-CoA reductase inhibitors
- Indications Myocardial infarction
- Focus Therapeutic Use
- 03 Jun 2015 New trial record